Wegovy, Zepbound and Belly Fat
Digest more
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.
President Trump announced an executive order to significantly reduce U.S. drug prices, aiming to align with costs in other nations. Eli Lilly's Zepbound drug outperforms Wegovy in a weight-loss trial.